# Strategic Innovation Investments by Multinational Drugmakers to Boost India’s Pharmaceutical Sector

- Link: https://www.thailand-business-news.com/health/200159-strategic-innovation-investments-by-multinational-drugmakers-to-boost-indias-pharmaceutical-sector
- Published: 2025-03-07T05:50:00+07:00
- Author: News Desk

**Multinational drugmakers are establishing technology centers in India, leveraging
its digital strengths for global operations. Investments like Amgen’s $200 million
in Hyderabad aim to enhance R&D and innovation in pharmaceuticals.**

**Key View**

ADVERTISEMENT

 * The establishment of technology and innovation centers in India by multinational
   drugmakers signals a strategic shift towards leveraging India’s strengths in 
   digital capabilities to support global operations.
 * Ongoing public sector efforts will support India’s pharmaceutical market growth.
 * The innovation centres will help catalyse domestic R&D innovation; however, long-
   term sustainability will depend on development of local talent and research infrastructure.

**The establishment of technology and innovation centers in India by multinational
drugmakers signals a strategic shift towards leveraging India’s strengths in digital
capabilities to support global operations. **On February 24 2025, Amgen announced
a USD200mn investment to establish a new technology and innovation center in Hyderabad,
India. This facility aims to enhance Amgen’s digital capabilities using artificial
intelligence and data science to boost its pipeline of medicines. Amgen India will
be important in driving innovation by developing and deploying technology and life
sciences solutions to enhance Amgen’s digital capabilities globally. Hyderabad, 
the capital of Telangana, has emerged as a prominent pharmaceutical hub in India,
attracting global pharmaceutical companies and investors. Hyderabad’s pharmaceutical
is significantly complemented by Genome Valley, which is India’s largest systematically
planned life sciences manufacturing cluster. Amgen’s announcement follows Eli Lilly’s
inauguration of the Lilly Capability Center India (LCCI) in Hyderabad in January
2025. The centre will focus on expanding automation, artificial intelligence (AI),
software product engineering and cloud computing to support Eli Lilly’s global operations.
Hyderabad is already home to companies like Bristol Myers Squibb, Roche, Bayer, 
Thermo Fisher Scientific and Sandoz. As such, India’s position as a hub for life
sciences and technology innovation in the Asia-Pacific (APAC) region is set to strengthen,
with significant investments from global pharmaceutical companies.

India’s pharmaceutical sector stands at a pivotal juncture as multinational drugmakers
increasingly recognize the country’s potential for strategic innovation investments.
This shift promises to enhance the industry’s global competitiveness and bolster
its position as a leading hub for pharmaceutical manufacturing and research. With
its rich pool of scientific talent and established infrastructure, India offers 
a fertile ground for multinational companies to develop and commercialize new drug
technologies.

### Related**Posts**

###  󠀁[ASEAN Medical Tourism: Healthcare Growth and Investment Opportunities](https://www.thailand-business-news.com/health/340226-asean-medical-tourism-healthcare-growth-and-investment-opportunities)󠁿

###  󠀁[Thailand Business News | Morning Briefing | Tuesday, 17 November 2026](https://www.thailand-business-news.com/news/340738-thailand-business-news-morning-briefing-tuesday-17-november-2026)󠁿

###  󠀁[Thailand Business News | Morning Briefing | Thailand · ASEAN · Asia-Pacific markets](https://www.thailand-business-news.com/asean/340181-thailand-business-news-morning-briefing-thailand-%c2%b7-asean-%c2%b7-asia-pacific-markets)󠁿

###  󠀁[Amazing Thailand Grand Diwali Festival 2026 lights up three provinces this November](https://www.thailand-business-news.com/tourism/337779-amazing-thailand-grand-diwali-festival-2026-lights-up-three-provinces-this-november)󠁿

Investments from these global giants will enable Indian pharmaceutical companies
to adopt cutting-edge technologies such as artificial intelligence, personalized
medicine, and advanced biological manufacturing processes. These innovations not
only streamline drug development but also improve patient outcomes by delivering
more targeted therapies. Moreover, the collaboration between local firms and multinational
players could lead to knowledge transfer, fostering an environment of continuous
improvement and research excellence.

As India strengthens its regulatory frameworks and intellectual property protections,
the attractiveness of its pharmaceutical landscape will only grow. Multinational
investments will not only stimulate economic growth but also enhance access to affordable
medicines, ensuring that India remains a vital player in the global healthcare ecosystem.
Ultimately, this influx of innovation-driven capital is set to transform India’s
pharmaceutical sector, paving the way for breakthroughs that benefit patients both
locally and worldwide.
[Read More](https://www.fitchsolutions.com/bmi/pharmaceuticals/indias-pharmaceutical-sector-will-benefit-strategic-innovation-investments-multinational-drugmakers-03-03-2025)
